PEARL: Ligelizumab in CSU

Key messages

• Ligelizumab is a high-affinity, next-generation anti-IgE antibody.
• Phase 3 PEARL results show good efficacy profile on urticaria activity, and superiority to placebo – but not to omalizumab.
• The drug was well tolerated, consistent with previous studies, and with no new signals.
• Ligelizumab may represent a new option for patients with chronic spontaneous urticaria.